| Steven Jay Landau, MD | |
|
707 Bryant St, Statesville, NC 28677-4142 | |
| (704) 873-5224 | |
| Not Available |
| Full Name | Steven Jay Landau |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 31 Years |
| Location | 707 Bryant St, Statesville, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609868132 | NPI | - | NPPES |
| 5900081 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 9500386 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Iredell Memorial Hospital Inc | Statesville, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Piedmont Healthcare Pa | 9638070683 | 222 |
News Archive
The percentage of pregnant women undergoing a repeat Cesarean section (C-section) delivery jumped from 65 percent to 90 percent between 1997 and 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
The American Cancer Society, the American College of Radiology, and the U.S. Multi-Society Task Force on Colorectal Cancer (a group that comprises representatives from the American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy) have released the first-ever joint consensus guidelines for colorectal cancer screening.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
› Verified 2 days ago
| Entity Name | Piedmont Healthcare Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912999897 PECOS PAC ID: 9638070683 Enrollment ID: O20040114000339 |
News Archive
The percentage of pregnant women undergoing a repeat Cesarean section (C-section) delivery jumped from 65 percent to 90 percent between 1997 and 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
The American Cancer Society, the American College of Radiology, and the U.S. Multi-Society Task Force on Colorectal Cancer (a group that comprises representatives from the American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy) have released the first-ever joint consensus guidelines for colorectal cancer screening.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven Jay Landau, MD 650 Signal Hill Drive Ext, Po Box 1845, Statesville, NC 28625-4353 Ph: (704) 873-4277 | Steven Jay Landau, MD 707 Bryant St, Statesville, NC 28677-4142 Ph: (704) 873-5224 |
News Archive
The percentage of pregnant women undergoing a repeat Cesarean section (C-section) delivery jumped from 65 percent to 90 percent between 1997 and 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.
The American Cancer Society, the American College of Radiology, and the U.S. Multi-Society Task Force on Colorectal Cancer (a group that comprises representatives from the American College of Gastroenterology, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy) have released the first-ever joint consensus guidelines for colorectal cancer screening.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
Onyx Pharmaceuticals, Inc. today announced that the company has begun enrollment in the ASPIRE trial, a Phase 3 international clinical trial evaluating carfilzomib in combination with lenalidomide (Revlimid®) and low dose dexamethasone in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.
› Verified 2 days ago
Mark L Prendergast, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 707 Bryant St, Statesville, NC 28677 Phone: 704-873-5224 | |
Alan E Deddens, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 707 Bryant St, Statesville, NC 28677 Phone: 704-873-5224 | |
Angelia Smith Natili, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 707 Bryant St, Statesville, NC 28677 Phone: 704-873-5224 | |
Ronel Rocha Enrique, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 556 Kitchings Dr, Statesville, NC 28677 Phone: 704-838-8255 |